行情

SLS

SLS

Galena生物制药
NASDAQ

实时行情|Nasdaq Last Sale

2.940
-0.040
-1.34%
盘后: 2.870 -0.07 -2.38% 19:30 01/24 EST
开盘
2.950
昨收
2.980
最高
2.970
最低
2.815
成交量
32.86万
成交额
--
52周最高
82.50
52周最低
2.750
市值
1,687.03万
市盈率(TTM)
-0.0012
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SLS 新闻

  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前
  • 瑞幸咖啡捐赠1000万元 助力疫情防控
  • 新浪科技.3小时前
  • 法国撤侨方案:大巴先送至长沙隔离14日
  • 观察者网.4小时前
  • 贝索斯手机遭入侵 手机窃听再次成为焦点
  • 新浪科技.4小时前

更多

所属板块

制药
-1.85%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

SLS 简况

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
展开

Webull提供Sellas Life Sciences Group Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。